Limits...
ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T, Noguchi M - Cancer Sci. (2014)

Bottom Line: Array-comparative genomic hybridization indicated frequent amplification at chromosome 3q26.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier curves analyzed using the log–rank test showing the overall survival (a) and relapse-free survival (b) of 144 patients with stage I adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317802&req=5

fig03: Kaplan–Meier curves analyzed using the log–rank test showing the overall survival (a) and relapse-free survival (b) of 144 patients with stage I adenocarcinoma.

Mentions: From the cDNA microarray data, 144 early-stage (pStage I) adenocarcinomas were divided into two groups showing high (n = 22) and low (n = 122) expression of ECT2. As shown in Figure 3, the ECT2 high group showed a significantly poorer outcome in terms of both OS rate and RFS rate. Moreover, multivariate analysis showed that ECT2 overexpression was an independent prognostic factor, similar to vascular invasion (Table 3).


ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T, Noguchi M - Cancer Sci. (2014)

Kaplan–Meier curves analyzed using the log–rank test showing the overall survival (a) and relapse-free survival (b) of 144 patients with stage I adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317802&req=5

fig03: Kaplan–Meier curves analyzed using the log–rank test showing the overall survival (a) and relapse-free survival (b) of 144 patients with stage I adenocarcinoma.
Mentions: From the cDNA microarray data, 144 early-stage (pStage I) adenocarcinomas were divided into two groups showing high (n = 22) and low (n = 122) expression of ECT2. As shown in Figure 3, the ECT2 high group showed a significantly poorer outcome in terms of both OS rate and RFS rate. Moreover, multivariate analysis showed that ECT2 overexpression was an independent prognostic factor, similar to vascular invasion (Table 3).

Bottom Line: Array-comparative genomic hybridization indicated frequent amplification at chromosome 3q26.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Show MeSH
Related in: MedlinePlus